Insider Sale: President and CEO at EXAS sold 155,417 Shares

Tuesday, Dec 30, 2025 7:07 pm ET1min read
EXAS--

Conroy Kevin T, a President and CEO at Exact Sciences (NASDAQ: EXAS), sold 155,417 shares of the company on Dec 23, 2025, for an estimated $15,824,559. This was a sale of approximately 11.2% of their shares of this class of stock. Following this trade, they now own 1,234,970 shares of this class of EXAS stock.

Exact Sciences Insider Trading Activity

Exact Sciences insiders have traded EXAS stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of EXAS stock by insiders over the last 6 months:

  • Zanotti Katherine S sold 12,000 shares for an estimated $780,000.
  • ORVILLE JACOB A (EVP, GM, Screening) sold 5,000 shares for an estimated $375,000.
  • Herriott James (SVP, General Counsel & Sec) has made 0 purchases and 3 sales selling 4,000 shares for an estimated $265,120.
  • Baranick Brian (EVP, GM, Precision Oncology) sold 2,858 shares for an estimated $200,289.
  • Doyle James Edward has made 0 purchases and 2 sales selling 3,485 shares for an estimated $182,400.

Exact Sciences Hedge Fund Activity

We have seen 3 institutional investors add shares of EXAS stock to their portfolio, and 2 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • Dekabank Deutsche Girozentrale added 458,222 shares of EXAS, for an estimated $26,253,556
  • Massachusetts Financial Services Company removed 398,025 shares of EXAS, for an estimated $21,775,947
  • Baillie Gifford & Co added 270,023 shares of EXAS, for an estimated $14,762,514
  • Truist Financial Corporation added 16,606 shares of EXAS, for an estimated $908,515
  • Voya Investment Management Llc removed 548 shares of EXAS, for an estimated $29,981

Exact Sciences Revenue

Exact Sciences had revenues of $850.7M in Q3 2025. This represents a 20.05% increase from the same period last year.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet